Literature DB >> 10963356

Sequestration of iron by Lewy bodies in Parkinson's disease.

R J Castellani1, S L Siedlak, G Perry, M A Smith.   

Abstract

Central to the oxidative stress hypothesis of Parkinson's disease (PD) pathogenesis is the ability of iron to generate hydroxyl radicals via the Fenton reaction, and the consistent demonstration of iron elevation in the pars compacta region of the substantia nigra. However, uncertainty exists as to whether the excess iron exists in a state suitable for redox chemistry. Here, using a method we developed that detects redox-active iron in situ, we were able to demonstrate strong labeling of Lewy bodies in substantia nigra pars compacta neurons in PD. In contrast, cortical Lewy bodies in cases of Lewy body variant of Alzheimer's disease were unstained. While the presence of elevated iron in PD substantiates the oxidative stress hypothesis, one must remember that these are viable neurons, indicating that Lewy bodies may act to sequester iron in PD brains in a protective, rather than degenerative, mechanism. The absence of redox-active iron in neocortical Lewy bodies highlights a fundamental difference between cortical and brain stem Lewy bodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963356     DOI: 10.1007/s004010050001

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  65 in total

1.  The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.

Authors:  N Ostrerova-Golts; L Petrucelli; J Hardy; J M Lee; M Farer; B Wolozin
Journal:  J Neurosci       Date:  2000-08-15       Impact factor: 6.167

Review 2.  Paraquat and iron exposure as possible synergistic environmental risk factors in Parkinson's disease.

Authors:  Julie K Andersen
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

Review 3.  Molecular interactions of amyloid nanofibrils with biological aggregation modifiers: implications for cytotoxicity mechanisms and biomaterial design.

Authors:  Durga Dharmadana; Nicholas P Reynolds; Charlotte E Conn; Céline Valéry
Journal:  Interface Focus       Date:  2017-06-16       Impact factor: 3.906

4.  α-Synuclein Over-Expression Induces Increased Iron Accumulation and Redistribution in Iron-Exposed Neurons.

Authors:  Richard Ortega; Asuncion Carmona; Stéphane Roudeau; Laura Perrin; Tanja Dučić; Eleonora Carboni; Sylvain Bohic; Peter Cloetens; Paul Lingor
Journal:  Mol Neurobiol       Date:  2015-04-02       Impact factor: 5.590

5.  Synergistic effects of environmental risk factors and gene mutations in Parkinson's disease accelerate age-related neurodegeneration.

Authors:  Jun Peng; May Lin Oo; Julie K Andersen
Journal:  J Neurochem       Date:  2010-11-04       Impact factor: 5.372

Review 6.  Considerations for measuring iron in post-mortem tissue of Parkinson's disease patients.

Authors:  Dominic J Hare; Manfred Gerlach; Peter Riederer
Journal:  J Neural Transm (Vienna)       Date:  2012-09-13       Impact factor: 3.575

7.  Binding of alpha-synuclein with Fe(III) and with Fe(II) and biological implications of the resultant complexes.

Authors:  Yong Peng; Chengshan Wang; Howard H Xu; You-Nian Liu; Feimeng Zhou
Journal:  J Inorg Biochem       Date:  2009-11-18       Impact factor: 4.155

8.  Abnormal iron metabolism and oxidative stress in mice expressing a mutant form of the ferritin light polypeptide gene.

Authors:  Ana G Barbeito; Holly J Garringer; Martin A Baraibar; Xiaoying Gao; Miguel Arredondo; Marco T Núñez; Mark A Smith; Bernardino Ghetti; Ruben Vidal
Journal:  J Neurochem       Date:  2009-03-30       Impact factor: 5.372

Review 9.  Redox imbalance in Parkinson's disease.

Authors:  Shankar J Chinta; Julie K Andersen
Journal:  Biochim Biophys Acta       Date:  2008-03-04

10.  Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease.

Authors:  Bo Su; Haihua Liu; Xinglong Wang; Shu G Chen; Sandra L Siedlak; Eisaku Kondo; Raymond Choi; Atsushi Takeda; Rudy J Castellani; George Perry; Mark A Smith; Xiongwei Zhu; Hyoung-Gon Lee
Journal:  Mol Neurodegener       Date:  2009-07-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.